COVID-19大流行期间的血栓栓塞与抗凝治疗:抗凝论坛的临时临床指导
本文由抗凝论坛(北美抗凝治疗提供者组织)发布临时临床指导,针对COVID-19患者。COVID-19重症可导致细胞因子风暴、全身炎症反应和凝血病,提示预后不良;COVID-19诱导的凝血病(CIC)似乎比脓毒症相关DIC更倾向于血栓形成而非出血。CIC被推测为对COVID-19的不受控免疫血栓反应,越来越多的证据显示危重患者中出现静脉和动脉血栓栓塞事件。该指导讨论住院和出院后VTE预防、疑似但未确诊VTE的治疗、实验室监测、相关抗凝治疗以及优化COVID-19患者护理过渡的关键要素。
要点
- COVID-19重症可导致细胞因子风暴、全身炎症反应和凝血病,提示预后不良。
- COVID-19诱导的凝血病(CIC)似乎比脓毒症相关DIC更倾向于血栓形成而非出血。
- 越来越多的证据显示危重COVID-19患者中出现静脉和动脉血栓栓塞事件。
- 抗凝论坛发布临时临床指导,讨论住院和出院后VTE预防、疑似未确诊VTE治疗、实验室监测及抗凝治疗。
适用人群与场景
- COVID-19患者,包括住院和出院后患者。
研究设计与关键结果
- 本文为抗凝论坛发布的临时临床指导,讨论COVID-19患者住院和出院后VTE预防、疑似但未确诊VTE的治疗、实验室监测、相关抗凝治疗以及优化护理过渡的关键要素。
证据类型、等级与局限
- 证据类型:临床指导(指南/共识)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
指南或共识出处
- 抗凝论坛(Anticoagulation Forum)临时临床指导,发表于Journal of Thrombosis and Thrombolysis。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases, result in cytokine storm, systemic inflammatory response and coagulopathy that is prognostic of poor outcomes. While some, but not all, laboratory findings appear similar to sepsis-associated disseminated intravascular coagulopathy (DIC), COVID-19- induced coagulopathy (CIC) appears to be more prothrombotic than hemorrhagic. It has been postulated that CIC may be an uncontrolled immunothrombotic response to COVID-19, and there is growing evidence of venous and arterial thromboembolic events in these critically ill patients. Clinicians around the globe are challenged with rapidly identifying reasonable diagnostic, monitoring and anticoagulant strategies to safely and effectively manage these patients. Thoughtful use of proven, evidence-based approaches must be carefully balanced with integration of rapidly emerging evidence and growing experience. The goal of this document is to provide guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of anticoagulant therapies in patients with COVID-19. We discuss in-hospital and post-discharge venous thromboembolism (VTE) prevention, treatment of suspected but unconfirmed VTE, laboratory monitoring of COVID-19, associated anticoagulant therapies, and essential elements for optimized transitions of care specific to patients with COVID-19.
参考来源
- Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020. PMID: 32440883. doi:10.1007/s11239-020-02138-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。